Immune Control of Tumors by Antigen Presentation Improvement

REMEDI MM, BONACCI G, VIDES MA, DONADIO AC

TUMOR BIOLOGY

Karger

Año: 2003 vol. 24 p. 228 - 228

1010-4283

p class="MsoBodyTextIndent3" style="MARGIN: 0cm 0cm 0pt 36pt; LINE-HEIGHT: normal">Tumor cells cannot activate T-lymphocytes, since they do not usually express major histocompatibility complex (MHC) class II molecules. Thus, tumor antigens can only be presented indirectly to T cells through professional antigen-presenting cells (APC). In our laboratory, we have treated a tumor cells line (Tu1-A) – derived from an induced rat mammary sarcoma – in order to increase the expression of MHC class I and class II molecules. In our tumor model, the transference of these induced cells into normal rats generated a tumor mass that exhibited a lower tumor growth rate and an earlier regression as compared to those observed in rats inoculated with wild-type Tu1-A cells. This earlier tumor regression was associated with the development of an antigen-specific immune response. 85-87% of the rats inboth groups rejected